Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. develops and commercializes drug-delivery technologies for subcutaneous administration of biologics and other injectable therapies. News about HALO commonly covers ENHANZE licensing agreements, Hypercon and Surf Bio hyperconcentration collaborations, partner product regulatory approvals, royalty-based revenue updates, and financial guidance.
The company also reports developments tied to its proprietary products Hylenex and XYOSTED, drug-device combination products using auto-injector technologies, and collaborations with pharmaceutical and biotechnology companies in oncology, inflammatory disease and other therapeutic areas.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced plans to release its first-quarter 2023 financial and operating results on May 9, 2023, after the trading day concludes. A conference call will follow at 4:30 p.m. ET to discuss the results, accessible via pre-registration.
The call will also be available as a live webcast on the company's website. Halozyme is focused on enhancing patient experiences through its innovative ENHANZE® technology, which improves the delivery of injected medications. As of now, it has impacted over 700,000 patients globally.
Halozyme partners with major pharmaceutical firms like Roche and Pfizer, and it has a range of commercial products, including XYOSTED®, TLANDO®, and NOCDURNA®.
Halozyme Therapeutics (NASDAQ: HALO) announced that the recent decision by the European Patent Office regarding a co-formulation patent for DARZALEX FASPRO® will not affect its U.S. and European royalty revenues through at least 2030. The company reaffirms its 2023 revenue guidance, estimating total revenue between $815 million and $845 million, and royalty revenue between $445 million and $455 million. Despite the revocation of the European Patent EP3370770B1, Halozyme expects to maintain royalty payments from Janssen. A written decision is forthcoming, and an appeal could suspend the decision temporarily.